HC Wainwright Analysts Decrease Earnings Estimates for EYPT

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($2.15) per share for the year, down from their prior forecast of ($2.09). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

Several other analysts also recently weighed in on the stock. Chardan Capital lifted their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 8th. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. Scotiabank started coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Finally, Jefferies Financial Group started coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

EyePoint Pharmaceuticals Stock Performance

EYPT stock opened at $10.49 on Thursday. The stock’s fifty day moving average is $9.71 and its two-hundred day moving average is $9.91. The stock has a market capitalization of $561.42 million, a price-to-earnings ratio of -5.25 and a beta of 1.50. EyePoint Pharmaceuticals has a 1 year low of $5.86 and a 1 year high of $30.99.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EYPT. Charles Schwab Investment Management Inc. boosted its position in shares of EyePoint Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after purchasing an additional 7,967 shares in the last quarter. Intech Investment Management LLC acquired a new stake in EyePoint Pharmaceuticals during the third quarter valued at approximately $136,000. GSA Capital Partners LLP boosted its holdings in EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after buying an additional 18,616 shares in the last quarter. Greenwich Wealth Management LLC grew its position in EyePoint Pharmaceuticals by 8.3% in the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after buying an additional 900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after buying an additional 4,172 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.